Scotland reimburses five drugs, including two NICE rejects
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium (SMC) has given the go-ahead for five products to be reimbursed by NHS Scotland, including two which were rejected by its counterpart in England and Wales, NICE. The five drugs approved are Roche's Gazyvaro (obinutuzumab), Eli Lilly's Alimta (pemetrexed), Bayer's Adempas (riociguat), GlaxoSmithKline's Incruse (umeclidinium), and Celgene's Imnovid (pomalidomide).